Replimune Group (NASDAQ:REPL) Shares Up 5.1% - Should You Buy?

Key Points

• Replimune shares rose 5.1% to about $13.20 in mid-day trading, though volume was 76% below the average session level.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and a $12.00 average price target; JPMorgan recently raised its target to $21.00.
• The biotechnology company reported a quarterly loss of $0.72 per share, slightly worse than estimates, while insiders have sold 79,124 shares worth about $1.04 million over the past three months.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares shot up 5.1% during mid-day trading on Tuesday. The company traded as high as $13.26 and last traded at $13.1970. Approximately 1,085,693 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 4,544,294 shares. The stock had previously closed at $12.56.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Piper Sandler raised shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. Weiss Ratings downgraded shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Wolfe Research upgraded shares of Replimune Group to an "outperform" rating in a report on Tuesday, August 4th. Wedbush raised shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target on the stock in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. lifted their price target on Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Replimune Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The company's fifty day moving average price is $13.04 and its 200 day moving average price is $9.21. The company has a market cap of $1.23 billion, a PE ratio of -4.19 and a beta of 0.94.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities research analysts predict that Replimune Group, Inc. will post -2.81 earnings per share for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the transaction, the insider owned 224,215 shares of the company's stock, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares in the company, valued at approximately $3,082,366.56. This represents a 4.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 79,124 shares of company stock valued at $1,038,364. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently added to or reduced their stakes in REPL. Opaleye Management Inc. bought a new position in shares of Replimune Group during the 2nd quarter valued at approximately $15,332,000. WINTON GROUP Ltd purchased a new position in Replimune Group in the second quarter valued at approximately $115,000. Engineers Gate Manager LP lifted its stake in Replimune Group by 15.0% in the second quarter. Engineers Gate Manager LP now owns 172,998 shares of the company's stock valued at $1,915,000 after purchasing an additional 22,504 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Replimune Group during the second quarter valued at $151,000. Finally, Squarepoint Ops LLC bought a new position in Replimune Group during the second quarter valued at $1,454,000. Institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company's approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.